Previous 10 | Next 10 |
2024-02-13 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-12 14:38:53 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript CRISPR CMO who resigned after Casgevy approval lands...
— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older — EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and Intermittent Symptoms of Choking and Difficult or ...
− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial − TAK-861 Was Found to be Generally Safe and Well-Tolerated − Results Will be Presented at an Upcoming Scientific Congress Takeda ( TSE:4502/NYSE...
2024-02-02 17:11:18 ET More on CRISPR Therapeutics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off ...
2024-02-02 11:17:26 ET More on WisdomTree Japan Hedged Equity Fund: DXJ: Capitalizing On Japan's Bull Market, Mitigating FX Risk DXJ: Forward Indicator Is Showing Signs Of Weakness Tsunami warning in Japan after earthquake; Trading closed for New Year's Seeki...
2024-02-01 09:12:12 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shares gained around 6% premarket on Thursday after the biopharma firm entered into a global license and collaboration deal with Takeda ( NYSE: TAK ) for the development and commercialization of its inv...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
2024-02-01 02:26:23 ET Takeda Pharmaceutical ( NYSE: TAK ) said that Costa Saroukos, CFO, has decided to leave Takeda to return to his home-country of Australia to be closer to family. ... Read the full article on Seeking Alpha For further details ...
Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board directo...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...
LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase 1 CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Trans...
Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 16 1 Mezagitamab Had a Favorable Safety Profile, with No New Safety Signals 1 Takeda Plans to Initiate Gl...